...
首页> 外文期刊>Applied and Environmental Microbiology >Colonization and Immunomodulation by Lactobacillus reuteri ATCC 55730 in the Human Gastrointestinal Tract
【24h】

Colonization and Immunomodulation by Lactobacillus reuteri ATCC 55730 in the Human Gastrointestinal Tract

机译:罗伊氏乳杆菌ATCC 55730在人胃肠道中的定殖和免疫调节

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Lactobacillus reuteri ATCC 55730 is a probiotic (health-promoting) bacterium widely used as a dietary supplement. This study was designed to examine local colonization of the human gastrointestinal mucosa after dietary supplementation with L. reuteri ATCC 55730 and to determine subsequent immune responses at the colonized sites. In this open clinical investigation, 10 healthy volunteers and 9 volunteers with ileostomy underwent gastroscopy or ileoscopy and biopsy samples were taken from the stomach, duodenum, or ileum before and after supplementation with 4 × 108 CFU of live L. reuteri ATCC 55730 lactobacilli per day for 28 days. Biopsy specimen colonization was analyzed using fluorescence in situ hybridization with a molecular beacon probe, and immune cell populations were determined by immunostaining. Endogenous L. reuteri was detected in the stomach of 1 subject and the duodenum of 3 subjects (out of 10 subjects). After L. reuteri ATCC 55730 supplementation, the stomachs of 8 and the duodenums of all 10 subjects were colonized. Three ileostomy subjects (of six tested) had endogenous L. reuteri at baseline, while all six displayed colonization after L. reuteri supplementation. Gastric mucosal histiocyte numbers were reduced and duodenal B-lymphocyte numbers were increased by L. reuteri ATCC 55730 administration. Furthermore, L. reuteri administration induced a significantly higher amount of CD4-positive T-lymphocytes in the ileal epithelium. Dietary supplementation with the probiotic L. reuteri ATCC 55730 induces significant colonization of the stomach, duodenum, and ileum of healthy humans, and this is associated with significant alterations of the immune response in the gastrointestinal mucosa. These responses may be key components of a mechanism by which L. reuteri ATCC 55730 exerts its well-documented probiotic effects in humans.
机译:罗伊氏乳杆菌ATCC 55730是一种益生菌(促进健康)细菌,广泛用作膳食补充剂。本研究旨在检查膳食补充罗伊氏乳杆菌ATCC 55730后人胃肠道黏膜的局部定植,并确定随后在定植部位的免疫反应。在这项公开的临床研究中,每天补充胃液,十二指肠或回肠的胃,十二指肠或回肠,在每天补充4×108 CFU活的罗伊氏乳杆菌ATCC 55730乳杆菌后,对10名健康志愿者和9名接受回肠造口术的志愿者进行胃镜或回肠镜检查和活检。持续28天。使用分子信标探针通过荧光原位杂交分析活检标本定植,并通过免疫染色确定免疫细胞群。在1名受试者的胃和3名受试者的十二指肠(10名受试者)中检测到内源性罗伊氏乳杆菌。补充罗伊氏乳杆菌ATCC 55730后,将8位患者的胃和所有10位受试者的十二指肠定植。三名回肠造口术受试者(六名接受测试的受试者)在基线时具有内源性罗伊氏乳杆菌,而全部六名在补充罗伊氏乳杆菌后均显示出定植。通过罗伊氏乳杆菌ATCC 55730给药,胃粘膜组织细胞数量减少,十二指肠B淋巴细胞数量增加。此外,罗伊氏乳杆菌的施用在回肠上皮中诱导了明显更高数量的CD4阳性T淋巴细胞。膳食补充益生菌罗伊氏乳杆菌ATCC 55730会诱导健康人的胃,十二指肠和回肠明显集聚,这与胃肠道粘膜免疫反应的显着改变有关。这些反应可能是罗伊氏乳杆菌ATCC 55730在人类中发挥其有据可查的益生菌作用的机制的关键组成部分。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号